West Pharmaceutical Services (NYSE:WST) Sets New 12-Month High – Here’s Why

Shares of West Pharmaceutical Services, Inc. (NYSE:WST) hit a new 52-week high on Thursday . The stock traded as high as $323.29 and last traded at $323.4840, with a volume of 710743 shares changing hands. The stock had previously closed at $312.55.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on WST shares. Evercore reissued an “outperform” rating on shares of West Pharmaceutical Services in a report on Friday, April 24th. Jefferies Financial Group reissued a “buy” rating and issued a $295.00 price objective on shares of West Pharmaceutical Services in a report on Tuesday, February 10th. Morgan Stanley set a $315.00 price objective on shares of West Pharmaceutical Services in a report on Monday, April 27th. Zacks Research lowered shares of West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a report on Tuesday, April 14th. Finally, Citigroup reissued a “buy” rating on shares of West Pharmaceutical Services in a report on Friday, April 24th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $322.89.

West Pharmaceutical Services Trading Up 1.3%

The business’s 50-day simple moving average is $261.47 and its two-hundred day simple moving average is $264.28. The firm has a market capitalization of $23.04 billion, a price-to-earnings ratio of 43.60, a PEG ratio of 2.69 and a beta of 1.17. The company has a quick ratio of 2.04, a current ratio of 2.71 and a debt-to-equity ratio of 0.07.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.68 by $0.45. The business had revenue of $844.90 million for the quarter, compared to the consensus estimate of $779.68 million. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The business’s revenue was up 21.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.45 EPS. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. Equities analysts forecast that West Pharmaceutical Services, Inc. will post 8.61 earnings per share for the current year.

West Pharmaceutical Services Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, May 6th. Investors of record on Wednesday, April 29th were issued a $0.22 dividend. This represents a $0.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date was Wednesday, April 29th. West Pharmaceutical Services’s payout ratio is currently 11.76%.

West Pharmaceutical Services announced that its board has initiated a stock buyback plan on Tuesday, February 17th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the medical instruments supplier to reacquire up to 5.6% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s management believes its shares are undervalued.

Insider Buying and Selling at West Pharmaceutical Services

In related news, CAO Chad Winters sold 896 shares of the business’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $300.67, for a total value of $269,400.32. Following the sale, the chief accounting officer owned 1,523 shares in the company, valued at approximately $457,920.41. The trade was a 37.04% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Annette F. Favorite sold 2,817 shares of the business’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $305.20, for a total value of $859,748.40. Following the completion of the sale, the vice president owned 16,828 shares in the company, valued at $5,135,905.60. This represents a 14.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On West Pharmaceutical Services

Several institutional investors and hedge funds have recently modified their holdings of WST. Elyxium Wealth LLC purchased a new stake in shares of West Pharmaceutical Services in the 4th quarter valued at $25,000. CYBER HORNET ETFs LLC purchased a new stake in shares of West Pharmaceutical Services in the 2nd quarter valued at $25,000. Cornerstone Planning Group LLC raised its holdings in shares of West Pharmaceutical Services by 90.9% in the 1st quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier’s stock valued at $26,000 after buying an additional 50 shares during the period. Bayban purchased a new stake in West Pharmaceutical Services during the 4th quarter worth about $27,000. Finally, Private Trust Co. NA increased its holdings in West Pharmaceutical Services by 156.4% during the 4th quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier’s stock worth $28,000 after purchasing an additional 61 shares during the period. Hedge funds and other institutional investors own 93.90% of the company’s stock.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.